{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:01:10Z","timestamp":1792483270780,"version":"4.5.0"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014926","name":"Acceleron","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2023,8,11]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional efficacy endpoints in pre-treated participants with pulmonary arterial hypertension (PAH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This<jats:italic>post hoc<\/jats:italic>analysis evaluated data from right heart catheterisation (RHC) and echocardiography (ECHO) obtained from the STELLAR trial. Changes from baseline in RHC and ECHO parameters were assessed at 24\u2005weeks. An analysis of covariance (ANCOVA) model was used to estimate differences in least squares means with treatment and randomisation stratification (mono\/double<jats:italic>versus<\/jats:italic>triple therapy; World Health Organization functional class II<jats:italic>versus<\/jats:italic>III) as fixed factors, and baseline value as covariate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Relative to placebo, treatment with sotatercept led to significant (all p&lt;0.0001 except where noted) improvements from baseline in mean pulmonary artery (PA) pressure (\u221213.9\u2005mmHg), pulmonary vascular resistance (\u2212254.8 dyn\u00b7s\u00b7cm<jats:sup>\u22125<\/jats:sup>), mean right atrial pressure (\u22122.7\u2005mmHg), mixed venous oxygen saturation (3.84%), PA elastance (\u22120.42\u2005mmHg\u00b7mL<jats:sup>\u22121<\/jats:sup>\u00b7beat<jats:sup>\u22121<\/jats:sup>), PA compliance (0.58\u2005mL\u00b7mmHg<jats:sup>\u22121<\/jats:sup>), cardiac efficiency (0.48\u2005mL\u00b7beat<jats:sup>\u22121<\/jats:sup>\u00b7mmHg<jats:sup>\u22121<\/jats:sup>), right ventricular (RV) work (\u22120.85\u2005g\u00b7m) and RV power (\u221232.70\u2005mmHg\u00b7L\u00b7min<jats:sup>\u22121<\/jats:sup>). ECHO showed improvements in tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary artery pressure ratio (0.12\u2005mm\u00b7mmHg<jats:sup>\u22121<\/jats:sup>), end-systolic and end-diastolic RV areas (\u22124.39\u2005cm<jats:sup>2<\/jats:sup>and \u22125.31\u2005cm<jats:sup>2<\/jats:sup>, respectively), tricuspid regurgitation and RV fractional area change (2.04% p&lt;0.050). No significant between-group changes from baseline were seen for TAPSE, heart rate, cardiac output, stroke volume or their indices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In pre-treated patients with PAH, sotatercept demonstrated substantial improvements in PA pressures, PA compliance, PA\u2013RV coupling and right heart function.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.01107-2023","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T12:50:14Z","timestamp":1694436614000},"page":"2301107","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":118,"title":["Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial"],"prefix":"10.1183","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-9143","authenticated-orcid":false,"given":"Rogerio","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2029-4419","authenticated-orcid":false,"given":"H. Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon R.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana R.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-0361","authenticated-orcid":false,"given":"Aaron B.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Kope\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janethe","family":"de Oliveira Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-2293","authenticated-orcid":false,"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"2024102103174639000_62.3.2301107.1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2207410","article-title":"Right ventricular failure","volume":"388","author":"Houston","year":"2023","journal-title":"N Engl J Med"},{"key":"2024102103174639000_62.3.2301107.2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.healun.2022.10.003","article-title":"Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: a COMPERA analysis","volume":"42","author":"Rosenkranz","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"2024102103174639000_62.3.2301107.3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41467-021-21961-3","article-title":"An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension","volume":"12","author":"Ryanto","year":"2021","journal-title":"Nat Commun"},{"key":"2024102103174639000_62.3.2301107.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02341-2020"},{"key":"2024102103174639000_62.3.2301107.5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","article-title":"Serum and pulmonary expression profiles in the activin signaling system in pulmonary arterial hypertension","volume":"147","author":"Guignabert","year":"2023","journal-title":"Circulation"},{"key":"2024102103174639000_62.3.2301107.6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10456-023-09873-w","article-title":"Diminished vasculogenesis under inflammatory conditions is mediated by activin A","volume":"26","author":"Manohar-Sindhu","year":"2023","journal-title":"Angiogenesis"},{"key":"2024102103174639000_62.3.2301107.7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"2024102103174639000_62.3.2301107.8","doi-asserted-by":"crossref","first-page":"1064290","DOI":"10.3389\/fcvm.2023.1064290","article-title":"Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure","volume":"10","author":"Joshi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2024102103174639000_62.3.2301107.9","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci Rep"},{"key":"2024102103174639000_62.3.2301107.10","doi-asserted-by":"crossref","unstructured":"Gomberg-Maitland M , McLaughlin VV , Badesch DB , et al. Long-term effects of sotatercept on right ventricular function: results from the PULSAR study. JACC Heart Fail 2023; in press [https:\/\/doi.org\/10.1016\/j.jchf.2023.05.030]. doi:10.1016\/j.jchf.2023.05.030","DOI":"10.1016\/j.jchf.2023.05.030"},{"key":"2024102103174639000_62.3.2301107.11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"16","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"2024102103174639000_62.3.2301107.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"2024102103174639000_62.3.2301107.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137511"},{"key":"2024102103174639000_62.3.2301107.14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1053-2498(00)00606-9","article-title":"Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study","volume":"20","author":"Channick","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"2024102103174639000_62.3.2301107.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2024102103174639000_62.3.2301107.16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102103174639000_62.3.2301107.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.06.091"},{"key":"2024102103174639000_62.3.2301107.18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijcard.2018.01.053","article-title":"Relevance of the TAPSE\/PASP ratio in pulmonary arterial hypertension","volume":"266","author":"Tello","year":"2018","journal-title":"Int J Cardiol"},{"key":"2024102103174639000_62.3.2301107.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2016.12.024"},{"key":"2024102103174639000_62.3.2301107.20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1152\/japplphysiol.00081.2023","article-title":"How to incorporate tricuspid regurgitation in right ventricular-pulmonary arterial coupling","volume":"135","author":"Yoshida","year":"2023","journal-title":"J Appl Physiol"},{"key":"2024102103174639000_62.3.2301107.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01950-1"},{"key":"2024102103174639000_62.3.2301107.22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"2024102103174639000_62.3.2301107.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00889-2017"},{"key":"2024102103174639000_62.3.2301107.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00740-2017"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01107-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:16:50Z","timestamp":1740381410000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01107-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,21]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1183\/13993003.01107-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01107-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}